研究能量平衡改变对慢性淋巴细胞白血病健康反应的作用 (HIT-CLL)
This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia. Investigators will randomise participants to either 12 weeks of supervised/semi-supervised exercise only, exercise + nutritional guidance, or no exercise.
研究概览
详细说明
This study aims to perform a randomised control trial of exercise or exercise plus nutritional guidance on the physiological and immunological health of adults diagnosed with chronic lymphocytic leukaemia (CLL). Recruited participants will be randomised to either 12 weeks of an exercise-only program, an exercise-plus nutritional guidance program or a no-exercise control group. Fasting blood samples collected at Baseline and 12 weeks will measure absolute CLL cell counts, immune function, and inflammatory and metabolic biomarkers. A series of physical fitness assessments will be assessed at baseline and 12 weeks to determine physiologic reserve and resilience against external stressors. Additionally, participants will be asked to return 12 weeks after completing the intervention to assess the legacy effects of the intervention on the same physiological and blood-based biomarkers of health.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Guildford、英国、GU2 7WG
- University of Surrey
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Confirmed diagnosis of CLL (including small lymphocytic leukaemia) as per the International Workshop on CLL Guidelines.
- Male or female ≥ 18 years of age
- Able to walk on a treadmill or cycle on an ergometer
- Pass the Physical Activity Readiness Questionnaires (PAR-Q and PAR-Q+)
Exclusion Criteria:
- Corticosteroid therapy initiated less than 7 days before study entry. Prednisone 10mg or less or equivalent is allowed. Topical or inhaled corticosteroids are permitted.
- Secondary malignancy within 3 years of study enrollment requiring intervention except for adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localised prostate cancer and PSA stable.
- Absolute contraindications to exercise: Recent (<6 months) acute cardiac event unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism and acute systemic infection.
- Significant orthopaedic limitations, musculoskeletal disease and/or injury. Due to the nature of the study, persons with known joint, muscle or other orthopaedic limitations that restrict physical activity may be excluded.
- Type I diabetes mellitus or uncontrolled Type II diabetes mellitus, or chronic obstructive pulmonary disease
- Uncontrolled blood pressure (≥180/90) at rest
- Known concurrent HIV, Hepatitis B or Hepatitis C
- Unable to comply with other study requirements
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:HIT Group
Exercise Only
|
Exercise training only |
|
实验性的:EXE+ Group
Exercise + Nutritional Guidance
|
Exercise Training + Nutritional Guidance |
|
无干预:Control Group
Control group will receive no exercise or nutritional guidance |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in absolute number of CD19+/CD5+ CLL cells at week 12
大体时间:Baseline and 12 weeks
|
A blood sample will be taken and assessed for CD19+/CD5+ CLL frequency using flow cytometry and total lymphocyte counts to determine the absolute number of CLL cells in x10^9/L |
Baseline and 12 weeks
|
|
Change from baseline in cardiorespiratory fitness (CRF: VO2peak) at week 12
大体时间:Baseline and 12 weeks
|
Cardiopulmonary exercise testing will be conducted to assess changes in fitness |
Baseline and 12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Frailty
大体时间:Baseline and 12 weeks
|
Frailty will be determined by a series of validated physical function tests that provide a score of 0-1(Robust), 2 (Pre-Frail), 3-5 (Frail) |
Baseline and 12 weeks
|
|
Muscle Strength and Endurance
大体时间:Baseline and 12 weeks
|
Estimated one repetition maximum and repetitions to failure using machine-based weights |
Baseline and 12 weeks
|
|
Muscle Health
大体时间:Baseline and 12 weeks
|
Ultrasound and near-infrared spectroscopy assessment of muscle fuel usage |
Baseline and 12 weeks
|
|
Change in Quality of Life using the EORCT-QLQ-C30
大体时间:Baseline and 12 weeks
|
Quality of life will be determined by the EORCT-QLQ-C30 questionnaire |
Baseline and 12 weeks
|
|
Change in muscle oxygen metabolism during a single bout of exercise
大体时间:Baseline and 12 weeks
|
Measurement of muscle oxygenation via near infrared spectroscopy during a single session of acute exercise |
Baseline and 12 weeks
|
|
Change in B-CLL Cell Function
大体时间:Baseline and 12 weeks
|
Measurement of in vitro B-CLL cell proliferation by flow cytometry |
Baseline and 12 weeks
|
|
Change in systemic and cellular bioenergetics
大体时间:Baseline and 12 weeks
|
Measurement of in vitro immune cell fuel utilisation by high resolution respirometry and mass spectrometry |
Baseline and 12 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Legacy Effect of Intervention on change in cardiorespiratory fitness (VO2peak) as measured by a cardiopulmonary exercise test
大体时间:12 weeks to 24 weeks
|
Reassessment of CRF following 12 weeks of unguided exercise training |
12 weeks to 24 weeks
|
|
Legacy Effect of Intervention on absolute number of CD19+/CD5+ CLL cells
大体时间:12 weeks to 24 weeks
|
Reassessment of absolute number of CD19+/CD5+ CLL cells following 12 weeks of unguided exercise training |
12 weeks to 24 weeks
|
合作者和调查者
调查人员
- 首席研究员:David Bartlett, PhD、University of Surrey
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.